Rene Phillips Kessler

Rene Kessler practices at Temple Physicians Inc. in Philadelphia, Pennsylvania.

Rene Kessler's NPI, 1356909329, was assigned on June 4, 2019. Rene Kessler holds Pennsylvania license MD476449.

Rene Kessler's primary practice is Temple Physicians Inc., at 133 W Hunting Park Ave, Philadelphia, PA 19140 in Philadelphia County. The practice phone is (215) 324-0600.

Rene Kessler's primary practice is Temple Physicians Inc. in Philadelphia, Pennsylvania. The medical group on file is Temple ReadyCare-Northeastern. Dmand AI also links Rene Kessler to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Rene Kessler practices. Vendor and product names are available with a free account.

Family medicine is Rene Kessler's primary specialty in the NPI Registry, under taxonomy code 207Q00000X. Rene Kessler is licensed in Pennsylvania.

CMS data shows 61 Medicare services from Rene Kessler across 2 procedure codes in 2024, for 42 Medicare patients. Medicare paid $6,283 for them. Every service was in an office.

CMS counts 42 Medicare patients who saw Rene Kessler in 2024. The largest group is 65 to 74, with 18 patients. 74% of them have high blood pressure, and 60% have high cholesterol. Their average risk score is 2.03, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Rene Kessler's median patient age at 49, with 62% women.

In 2024, Rene Kessler wrote 5,150 Medicare Part D claims for 313 patients. 81% of them were for generic drugs. CMS names the drug for 4,660 of them, across 79 drugs with 11 or more claims each, at $363,752 in total drug cost. In 2023, CMS named 2,099 claims across 53 drugs.

Rene Kessler accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Rene Kessler in 2012.

CMS Open Payments shows 80 general payments to Rene Kessler from 20 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Eli Lilly and Company paid the most, $325.